New York City Metropolitan Area
Life Singularity is a frontier deep-tech company building the predictive immune system for healthcare. Our agentic AI platform is designed to shift medicine from today's reactive "sick-care" model to a proactive, preventative paradigm, solving the multi-trillion-dollar problem of chronic disease. The Challenge: Today's healthcare systems react to the "domino cascade" of chronic illness, where conditions like diabetes progress into high-cost events like congestive heart failure. This approach is financially unsustainable and results in poor patient outcomes. A Breakthrough Solution: The Proactive Health Engine Our full-stack intelligence platform anticipates and neutralizes these threats. Our core innovation is the creation of deep, multi-modal phenotypes. Unlike simple genetic tests, we integrate a patient's entire life context—clinical records, labs, genetics, and thousands of Social and Environmental Determinants of Health—to create a high-resolution, dynamic picture of their future health trajectory. This is powered by our AI Multi-Agent Orchestrator, a proprietary Predictor-Critic framework, and a self-reinforcing IP Generation Engine that has already identified novel multi-markers for obesity. This allows for Advanced Risk Stratification with 93% predictive accuracy, Proactive Cohort Identification, and Personalized Intervention Matching. Validated by World-Class Organizations: Our technology and vision have been recognized by the world's leading organizations: • NVIDIA: An elite member of the NVIDIA Inception Program, providing unparalleled strategic GTM and technical support. • Microsoft: Achieved Level 5, the highest tier of the Microsoft for Startups Founders Hub. • Hatcher+: Selected from thousands of startups to be presented to a network of 25 partner VCs. • Global Scientific Community: Invited to the Exposome Moonshot Forum Steering Committee alongside Johns Hopkins, Harvard, and the WHO. Life Singularity is led by Sanjeev Wadhwa, a 30-year former executive from Ernst & Young and Johnson & Johnson, and is guided by a world-class team of fractional leaders from the Broad Institute of MIT and Harvard, Emory University, and the C-suite of the healthcare industry. We partner with payers and life science companies to build the future of preventative health. Learn more at www.LifeSingularity.com
🏷️ Building Frontier AI Action-Conditioned Clinical World Models & Individual Digital Twins 📝Traditional health tech remains structurally trapped in basic single-disease risk prediction that completely fails to capture the non-linear velocity of human physiological decay. At Life Singularity, we are shifting this entire paradigm by operating at the absolute frontier AI to pioneer an Action-Conditioned Clinical World Model engineered for early disease cascade prevention. Natively utilizing a Joint Embedding Predictive Architecture (JEPA), our platform maps an individual, patient-level Digital Twin that tracks the precise temporal velocity of multi-morbid decay. This functions as an algorithmic predictive playground, allowing live counterfactuals to verify the exact financial and healthspan (QALY) outcomes of an intervention before deploying capital. 🛡️ Core Architecture & Software Moats Our high-performance software infrastructure operationalizes trajectory synthesis across three complex layers: The 3D Patient Manifold: Utilizing custom Rotary Position Embeddings (RoPE), our engine treats irregular chronological clinical intervals as an explicit geometric dimension, calculating a patient's continuous Vectorized Metabolic Thrust (X(t) - X(t-1)). Deterministic Multi-Agent Reasoning: High-risk trajectories engage our open-weights, 120B parameter NVIDIA Nemotron Multi-Agent Specialist Council for recursive, multi-round Delphi Simulations to automate peer-review loops between virtual specialists, eliminating hallucinations. 🌐 Ecosystem Validation & Venture Scale Our vision and enterprise-grade deployment roadmap are validated by world-leading technology and healthcare institutions: NVIDIA Inception, Microsoft for Startups, member of the steering committee of the Exposome Moonshot Forum alongside Johns Hopkins, Harvard, and the World Health Organization (WHO), Starglobal partnership
Executive Leadership responsibilities for planning and leading new and ambitious growth venture development for hyperscale initiatives for EY. Served as Americas Leader for health innovations and life sciences in creating the "Collective Intent" solution framework and industry-leading thought leadership, aligning Pharma, Payer, Provider, Pharmacy, Insurance and non-traditional stakeholders around defining a multi-Billion-dollar value proposition, operationalizing the solution and establishing EY as a Global brand in the Industry. Commercialized the Patient Adherence / collective intent solution, replicated IP-based solutions with managed services across Life Sciences and Healthcare. Developed and led Purpose-Driven Transformations for R&D, Commercial and Healthcare Delivery based on "Collective Intent Care Networks" for creating outcomes-based patient-centric, primary care collaborative models for global market creation, incentivizing behavioral change, patient engagement, remote health care and a move from Volume to Value, to increase affordability, access and preventative care
Board-Level Executive Leadership responsibilities for planning and leading new and ambitious growth venture development for multi-billion-dollar initiatives for CSC with key imperatives to retain market leadership and enhance shareholder value. Direct reporting to CSC Healthcare board of directors and executive committee with responsibilities for determining global staff, investments, & budgets for venture management. Also, nominated for two additional leadership roles, first, to lead the strategy and business planning for global go-to-market including M&A, second, to lead the Global R&D portfolio. A Partner, P&L Executive and Worldwide Director of the R&D Life Sciences Practice with full responsibility for leveraging innovation as a core & driving development of new solutions (exceeding $1B+) with top-line revenue growth targets of $10MM annually & managing global pursuits in the $200MM-300MM range. Developed vision, strategy & operational plans with focus on innovative, collaborative business models & championed development of global strategies. Lead development of several new ventures to global market launch built on foundation of strategic partnerships
Provided strategic leadership for board-level business initiatives that introduced pioneering innovation to enhance J&J’s market leadership. Established a record of achievement and directed global teams in improving business results through interdependent partnering, creation of value-added services, in-depth understanding of business imperatives and clients’ key business drivers, as well as collaboration across organizations to meet shared business objectives. Championed the development and execution of “pioneering”, complex, large-scale, multi-million dollar, worldwide initiatives such as Supercomputing, Grid Computing, Bio-Informatics, e-business initiatives such as JNJGateway.com providing access J&J business partners from 180 countries, Drug Safety, Genomics research, and New Product Development accomplishing several efforts to provide strategic direction for the global business initiatives.
Founded a technology consultancy, providing consulting services to Fortune 20 companies, focusing on conception, execution and development of R&D applications and large-scale information management architectures.